trial · primary record
Cemsidomide
Multiple Myeloma (MM)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2029-06 |
| Primary endpoint | Safety and tolerability of cemsidomide in combination with elranatamab |
| Registry ID | NCT07280013 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:38.381Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07280013
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cemsidomide · compound